Article Text

other Versions

PDF
Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS)
  1. Dafna D Gladman (dafna.gladman{at}utoronto.ca)
  1. Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Canada
    1. Catherine T. Schentag (schentag{at}uhnres.utoronto.ca)
    1. Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Canada
      1. Brian D.M. Tom (brian.tom{at}mrc-bsu.cam.ac.uk)
      1. MRC Biostatistics Unit, Institute of Public Health,, United Kingdom
        1. Vinod Chandran (vinod.chandran{at}uhnres.utoronto.ca)
        1. Centre for Prognosis Studies in the Rheumatic Diseases, Canada
          1. John Brockbank (jbrockbank{at}tiscali.co.uk)
          1. MRC Biostatistics Unit, Institute of Public Health, United Kingdom
            1. Cheryl Rosen (c.rosen{at}utoronto.ca)
            1. Division of Dermatology, University Health Network, Canada
              1. Vernon T Farewell (vern.farewell{at}mrc-bsu.cam.ac.uk)
              1. MRC Biostatistics Unit, Institute of Public Health, United Kingdom

                Abstract

                Objective: To develop and validate a Psoriatic Arthritis screening questionnaire (ToPAS).

                Methods: The ToPAS was developed through review of items seen in patients with Psoriatic Arthritis (PsA) and evaluation by patients with PsA and other rheumatology patients, and was administered to consecutive consenting patients attending 5 clinics: PsA; Psoriasis; General dermatology; General rheumatology (excluding PsA patients); and Family medicine. All patients were assessed by a rheumatologist according to a standard protocol. A three-step analysis strategy was adopted: A stepwise logistic regression to identify the questions most important in discriminating between those with and without PsA; a logistic model was fitted to three clinically relevant domains for PsA: skin, joints and nails; a simpler weighting of each of the domains used in step 2. ROC curves were obtained based on these various models.

                Results: There were 134 patients from the PsA clinic; 123 with psoriasis; 118 from dermatology; 135 from rheumatology; 178 from family medicine. A simplified discriminatory score based on the skin, joint and nail domains gave results comparable to other methods with an observed overall sensitivity and specificity, based on a single cut point, of 86.8% and 93.1%. When the PsA patients were compared with each of the other 4 patient groups individually, the sensitivity and specificity of the ToPAS were: psoriasis 89.1%, 86.3%; dermatology 91.9%, 95.2%; rheumatology 92.6%, 85.7%; and family medicine 90.4%, 100%.

                Conclusion: Our simplified index is very good at classifying both those who are not diagnosed with PsA and those who are diagnosed with PsA.

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.